Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups

Background Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Approximately 15–20% of patients develop symptoms before their 18th birthday and are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, disease courses and outcomes vary s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lupus 2020-04, Vol.29 (5), p.474-481
Hauptverfasser: Massias, J S, Smith, E M D, Al-Abadi, E, Armon, K, Bailey, K, Ciurtin, C, Davidson, J, Gardner-Medwin, J, Haslam, K, Hawley, D P, Leahy, A, Leone, V, McErlane, F, Mewar, D, Modgil, G, Moots, R, Pilkington, C, Ramanan, A V, Rangaraj, S, Riley, P, Sridhar, A, Wilkinson, N, Beresford, M W, Hedrich, C M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 481
container_issue 5
container_start_page 474
container_title Lupus
container_volume 29
creator Massias, J S
Smith, E M D
Al-Abadi, E
Armon, K
Bailey, K
Ciurtin, C
Davidson, J
Gardner-Medwin, J
Haslam, K
Hawley, D P
Leahy, A
Leone, V
McErlane, F
Mewar, D
Modgil, G
Moots, R
Pilkington, C
Ramanan, A V
Rangaraj, S
Riley, P
Sridhar, A
Wilkinson, N
Beresford, M W
Hedrich, C M
description Background Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Approximately 15–20% of patients develop symptoms before their 18th birthday and are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, disease courses and outcomes vary significantly between JSLE patients and individuals with adult-onset SLE. This study aimed to identify age-specific clinical and/or serological patterns in JSLE patients enrolled to the UK JSLE Cohort Study. Methods Patient records were accessed and grouped based on age at disease-onset: pre-pubertal (≤7 years), peri-pubertal (8–13 years) and adolescent (14–18 years). The presence of American College of Rheumatology (ACR) classification criteria, laboratory results, disease activity [British Isles Lupus Assessment Group (BILAG) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) scores] and damage [Systemic Lupus International Collaborating Clinics (SLICC) damage index] were evaluated at diagnosis and last follow up. Results A total of 418 JSLE patients were included in this study: 43 (10.3%) with pre-pubertal disease onset; 240 (57.4%) with peri-pubertal onset and 135 (32.3%) were diagnosed during adolescence. At diagnosis, adolescent JSLE patients presented with a higher number of ACR criteria when compared with pre-pubertal and peri-pubertal patients [pBILAG2004 scores: 9(4–20] vs. 7(3–13] vs. 7(3–14], respectively, p = 0.015] with increased activity in the following BILAG domains: mucocutaneous (p = 0.025), musculoskeletal (p = 0.029), renal (p = 0.027) and cardiorespiratory (p = 0.001). Furthermore, adolescent JSLE patients were more frequently ANA-positive (p = 0.034) and exhibited higher anti-dsDNA titres (p = 0.001). Pre-pubertal individuals less frequently presented with leukopenia (p = 0.002), thrombocytopenia (p = 0.004) or low complement (p = 0.002) when compared with other age groups. No differences were identified in disease activity (pBILAG2004 score), damage (SLICC damage index) and the number of ACR criteria fulfilled at last follow up. Conclusions Disease presentations and laboratory findings vary significantly between age groups within a national cohort of JSLE patients. Patients diagnosed during adolescence exhibit greater disease activity and “classic” autoantibody, immune cell and complement patterns when compared with younger patients. This supports the hypothesis that pathomechanisms may vary between patient age group
doi_str_mv 10.1177/0961203320909156
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2390503512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203320909156</sage_id><sourcerecordid>2385726568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-2cbdc882f376718ef454f80fd62db4fa5f7a24d64f58048da4ef173e4a7c4c013</originalsourceid><addsrcrecordid>eNp1kc2PUyEUxYnROLW6d2VI3Lh5yje8jYlp_EomcaNrQnnQ0vCgAm-S_vdD7TjqJK5u4PzugXsPAC8xeouxlO_QKDBBlBI0ohFz8QisMJNy6PfkMVid5eGsX4FntR4QQhSP4im4ooRQKildgf0mhhSsidCkCUazzcW0XE7Q7k0xtrkSagu2wpDgYblxKUQ35FRdg_VUm5uDhXE5LhW6cmp7N_fu2k_Gllx72Tm4K3k51ufgiTexuhd3dQ1-fPr4ffNluP72-evmw_VgmSBtIHY7WaWIp1JIrJxnnHmF_CTItGXecC8NYZNgnivE1GSY81hSx4y0zCJM1-D9xfe4bGc3WZdaMVEfS5hNOelsgv5XSWGvd_lGS04U70tZgzd3BiX_XFxteg7VuhhNcnmpmlDFJRFcqI6-foAe8lJSH69TI-KIckw6hS7Ur5UU5-8_g5E-x6gfxthbXv09xH3D79w6MFyA2jf859X_Gt4CskinuQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2390503512</pqid></control><display><type>article</type><title>Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Massias, J S ; Smith, E M D ; Al-Abadi, E ; Armon, K ; Bailey, K ; Ciurtin, C ; Davidson, J ; Gardner-Medwin, J ; Haslam, K ; Hawley, D P ; Leahy, A ; Leone, V ; McErlane, F ; Mewar, D ; Modgil, G ; Moots, R ; Pilkington, C ; Ramanan, A V ; Rangaraj, S ; Riley, P ; Sridhar, A ; Wilkinson, N ; Beresford, M W ; Hedrich, C M</creator><creatorcontrib>Massias, J S ; Smith, E M D ; Al-Abadi, E ; Armon, K ; Bailey, K ; Ciurtin, C ; Davidson, J ; Gardner-Medwin, J ; Haslam, K ; Hawley, D P ; Leahy, A ; Leone, V ; McErlane, F ; Mewar, D ; Modgil, G ; Moots, R ; Pilkington, C ; Ramanan, A V ; Rangaraj, S ; Riley, P ; Sridhar, A ; Wilkinson, N ; Beresford, M W ; Hedrich, C M</creatorcontrib><description>Background Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Approximately 15–20% of patients develop symptoms before their 18th birthday and are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, disease courses and outcomes vary significantly between JSLE patients and individuals with adult-onset SLE. This study aimed to identify age-specific clinical and/or serological patterns in JSLE patients enrolled to the UK JSLE Cohort Study. Methods Patient records were accessed and grouped based on age at disease-onset: pre-pubertal (≤7 years), peri-pubertal (8–13 years) and adolescent (14–18 years). The presence of American College of Rheumatology (ACR) classification criteria, laboratory results, disease activity [British Isles Lupus Assessment Group (BILAG) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) scores] and damage [Systemic Lupus International Collaborating Clinics (SLICC) damage index] were evaluated at diagnosis and last follow up. Results A total of 418 JSLE patients were included in this study: 43 (10.3%) with pre-pubertal disease onset; 240 (57.4%) with peri-pubertal onset and 135 (32.3%) were diagnosed during adolescence. At diagnosis, adolescent JSLE patients presented with a higher number of ACR criteria when compared with pre-pubertal and peri-pubertal patients [pBILAG2004 scores: 9(4–20] vs. 7(3–13] vs. 7(3–14], respectively, p = 0.015] with increased activity in the following BILAG domains: mucocutaneous (p = 0.025), musculoskeletal (p = 0.029), renal (p = 0.027) and cardiorespiratory (p = 0.001). Furthermore, adolescent JSLE patients were more frequently ANA-positive (p = 0.034) and exhibited higher anti-dsDNA titres (p = 0.001). Pre-pubertal individuals less frequently presented with leukopenia (p = 0.002), thrombocytopenia (p = 0.004) or low complement (p = 0.002) when compared with other age groups. No differences were identified in disease activity (pBILAG2004 score), damage (SLICC damage index) and the number of ACR criteria fulfilled at last follow up. Conclusions Disease presentations and laboratory findings vary significantly between age groups within a national cohort of JSLE patients. Patients diagnosed during adolescence exhibit greater disease activity and “classic” autoantibody, immune cell and complement patterns when compared with younger patients. This supports the hypothesis that pathomechanisms may vary between patient age groups.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203320909156</identifier><identifier>PMID: 32233733</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adolescent ; Adolescents ; Age ; Age groups ; Age of Onset ; Anti-DNA antibodies ; Autoantibodies ; Child ; Child development ; Clinical Laboratory Techniques ; Cohort Studies ; Diagnosis ; Disease Progression ; Female ; Health risk assessment ; Humans ; Inflammation ; Laboratories ; Leukopenia ; Lupus ; Lupus Erythematosus, Systemic - diagnosis ; Lupus Erythematosus, Systemic - pathology ; Male ; Patients ; Rheumatology ; Severity of Illness Index ; Sex Factors ; Systemic lupus erythematosus ; Thrombocytopenia ; United Kingdom</subject><ispartof>Lupus, 2020-04, Vol.29 (5), p.474-481</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020 2020 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-2cbdc882f376718ef454f80fd62db4fa5f7a24d64f58048da4ef173e4a7c4c013</citedby><cites>FETCH-LOGICAL-c462t-2cbdc882f376718ef454f80fd62db4fa5f7a24d64f58048da4ef173e4a7c4c013</cites><orcidid>0000-0002-8371-7597 ; 0000-0002-8911-4113 ; 0000-0002-1295-6179</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203320909156$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203320909156$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32233733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Massias, J S</creatorcontrib><creatorcontrib>Smith, E M D</creatorcontrib><creatorcontrib>Al-Abadi, E</creatorcontrib><creatorcontrib>Armon, K</creatorcontrib><creatorcontrib>Bailey, K</creatorcontrib><creatorcontrib>Ciurtin, C</creatorcontrib><creatorcontrib>Davidson, J</creatorcontrib><creatorcontrib>Gardner-Medwin, J</creatorcontrib><creatorcontrib>Haslam, K</creatorcontrib><creatorcontrib>Hawley, D P</creatorcontrib><creatorcontrib>Leahy, A</creatorcontrib><creatorcontrib>Leone, V</creatorcontrib><creatorcontrib>McErlane, F</creatorcontrib><creatorcontrib>Mewar, D</creatorcontrib><creatorcontrib>Modgil, G</creatorcontrib><creatorcontrib>Moots, R</creatorcontrib><creatorcontrib>Pilkington, C</creatorcontrib><creatorcontrib>Ramanan, A V</creatorcontrib><creatorcontrib>Rangaraj, S</creatorcontrib><creatorcontrib>Riley, P</creatorcontrib><creatorcontrib>Sridhar, A</creatorcontrib><creatorcontrib>Wilkinson, N</creatorcontrib><creatorcontrib>Beresford, M W</creatorcontrib><creatorcontrib>Hedrich, C M</creatorcontrib><title>Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Background Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Approximately 15–20% of patients develop symptoms before their 18th birthday and are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, disease courses and outcomes vary significantly between JSLE patients and individuals with adult-onset SLE. This study aimed to identify age-specific clinical and/or serological patterns in JSLE patients enrolled to the UK JSLE Cohort Study. Methods Patient records were accessed and grouped based on age at disease-onset: pre-pubertal (≤7 years), peri-pubertal (8–13 years) and adolescent (14–18 years). The presence of American College of Rheumatology (ACR) classification criteria, laboratory results, disease activity [British Isles Lupus Assessment Group (BILAG) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) scores] and damage [Systemic Lupus International Collaborating Clinics (SLICC) damage index] were evaluated at diagnosis and last follow up. Results A total of 418 JSLE patients were included in this study: 43 (10.3%) with pre-pubertal disease onset; 240 (57.4%) with peri-pubertal onset and 135 (32.3%) were diagnosed during adolescence. At diagnosis, adolescent JSLE patients presented with a higher number of ACR criteria when compared with pre-pubertal and peri-pubertal patients [pBILAG2004 scores: 9(4–20] vs. 7(3–13] vs. 7(3–14], respectively, p = 0.015] with increased activity in the following BILAG domains: mucocutaneous (p = 0.025), musculoskeletal (p = 0.029), renal (p = 0.027) and cardiorespiratory (p = 0.001). Furthermore, adolescent JSLE patients were more frequently ANA-positive (p = 0.034) and exhibited higher anti-dsDNA titres (p = 0.001). Pre-pubertal individuals less frequently presented with leukopenia (p = 0.002), thrombocytopenia (p = 0.004) or low complement (p = 0.002) when compared with other age groups. No differences were identified in disease activity (pBILAG2004 score), damage (SLICC damage index) and the number of ACR criteria fulfilled at last follow up. Conclusions Disease presentations and laboratory findings vary significantly between age groups within a national cohort of JSLE patients. Patients diagnosed during adolescence exhibit greater disease activity and “classic” autoantibody, immune cell and complement patterns when compared with younger patients. This supports the hypothesis that pathomechanisms may vary between patient age groups.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Age</subject><subject>Age groups</subject><subject>Age of Onset</subject><subject>Anti-DNA antibodies</subject><subject>Autoantibodies</subject><subject>Child</subject><subject>Child development</subject><subject>Clinical Laboratory Techniques</subject><subject>Cohort Studies</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Laboratories</subject><subject>Leukopenia</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - diagnosis</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Male</subject><subject>Patients</subject><subject>Rheumatology</subject><subject>Severity of Illness Index</subject><subject>Sex Factors</subject><subject>Systemic lupus erythematosus</subject><subject>Thrombocytopenia</subject><subject>United Kingdom</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc2PUyEUxYnROLW6d2VI3Lh5yje8jYlp_EomcaNrQnnQ0vCgAm-S_vdD7TjqJK5u4PzugXsPAC8xeouxlO_QKDBBlBI0ohFz8QisMJNy6PfkMVid5eGsX4FntR4QQhSP4im4ooRQKildgf0mhhSsidCkCUazzcW0XE7Q7k0xtrkSagu2wpDgYblxKUQ35FRdg_VUm5uDhXE5LhW6cmp7N_fu2k_Gllx72Tm4K3k51ufgiTexuhd3dQ1-fPr4ffNluP72-evmw_VgmSBtIHY7WaWIp1JIrJxnnHmF_CTItGXecC8NYZNgnivE1GSY81hSx4y0zCJM1-D9xfe4bGc3WZdaMVEfS5hNOelsgv5XSWGvd_lGS04U70tZgzd3BiX_XFxteg7VuhhNcnmpmlDFJRFcqI6-foAe8lJSH69TI-KIckw6hS7Ur5UU5-8_g5E-x6gfxthbXv09xH3D79w6MFyA2jf859X_Gt4CskinuQ</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Massias, J S</creator><creator>Smith, E M D</creator><creator>Al-Abadi, E</creator><creator>Armon, K</creator><creator>Bailey, K</creator><creator>Ciurtin, C</creator><creator>Davidson, J</creator><creator>Gardner-Medwin, J</creator><creator>Haslam, K</creator><creator>Hawley, D P</creator><creator>Leahy, A</creator><creator>Leone, V</creator><creator>McErlane, F</creator><creator>Mewar, D</creator><creator>Modgil, G</creator><creator>Moots, R</creator><creator>Pilkington, C</creator><creator>Ramanan, A V</creator><creator>Rangaraj, S</creator><creator>Riley, P</creator><creator>Sridhar, A</creator><creator>Wilkinson, N</creator><creator>Beresford, M W</creator><creator>Hedrich, C M</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8371-7597</orcidid><orcidid>https://orcid.org/0000-0002-8911-4113</orcidid><orcidid>https://orcid.org/0000-0002-1295-6179</orcidid></search><sort><creationdate>20200401</creationdate><title>Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups</title><author>Massias, J S ; Smith, E M D ; Al-Abadi, E ; Armon, K ; Bailey, K ; Ciurtin, C ; Davidson, J ; Gardner-Medwin, J ; Haslam, K ; Hawley, D P ; Leahy, A ; Leone, V ; McErlane, F ; Mewar, D ; Modgil, G ; Moots, R ; Pilkington, C ; Ramanan, A V ; Rangaraj, S ; Riley, P ; Sridhar, A ; Wilkinson, N ; Beresford, M W ; Hedrich, C M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-2cbdc882f376718ef454f80fd62db4fa5f7a24d64f58048da4ef173e4a7c4c013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Age</topic><topic>Age groups</topic><topic>Age of Onset</topic><topic>Anti-DNA antibodies</topic><topic>Autoantibodies</topic><topic>Child</topic><topic>Child development</topic><topic>Clinical Laboratory Techniques</topic><topic>Cohort Studies</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Laboratories</topic><topic>Leukopenia</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - diagnosis</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Male</topic><topic>Patients</topic><topic>Rheumatology</topic><topic>Severity of Illness Index</topic><topic>Sex Factors</topic><topic>Systemic lupus erythematosus</topic><topic>Thrombocytopenia</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Massias, J S</creatorcontrib><creatorcontrib>Smith, E M D</creatorcontrib><creatorcontrib>Al-Abadi, E</creatorcontrib><creatorcontrib>Armon, K</creatorcontrib><creatorcontrib>Bailey, K</creatorcontrib><creatorcontrib>Ciurtin, C</creatorcontrib><creatorcontrib>Davidson, J</creatorcontrib><creatorcontrib>Gardner-Medwin, J</creatorcontrib><creatorcontrib>Haslam, K</creatorcontrib><creatorcontrib>Hawley, D P</creatorcontrib><creatorcontrib>Leahy, A</creatorcontrib><creatorcontrib>Leone, V</creatorcontrib><creatorcontrib>McErlane, F</creatorcontrib><creatorcontrib>Mewar, D</creatorcontrib><creatorcontrib>Modgil, G</creatorcontrib><creatorcontrib>Moots, R</creatorcontrib><creatorcontrib>Pilkington, C</creatorcontrib><creatorcontrib>Ramanan, A V</creatorcontrib><creatorcontrib>Rangaraj, S</creatorcontrib><creatorcontrib>Riley, P</creatorcontrib><creatorcontrib>Sridhar, A</creatorcontrib><creatorcontrib>Wilkinson, N</creatorcontrib><creatorcontrib>Beresford, M W</creatorcontrib><creatorcontrib>Hedrich, C M</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Massias, J S</au><au>Smith, E M D</au><au>Al-Abadi, E</au><au>Armon, K</au><au>Bailey, K</au><au>Ciurtin, C</au><au>Davidson, J</au><au>Gardner-Medwin, J</au><au>Haslam, K</au><au>Hawley, D P</au><au>Leahy, A</au><au>Leone, V</au><au>McErlane, F</au><au>Mewar, D</au><au>Modgil, G</au><au>Moots, R</au><au>Pilkington, C</au><au>Ramanan, A V</au><au>Rangaraj, S</au><au>Riley, P</au><au>Sridhar, A</au><au>Wilkinson, N</au><au>Beresford, M W</au><au>Hedrich, C M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>29</volume><issue>5</issue><spage>474</spage><epage>481</epage><pages>474-481</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Background Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Approximately 15–20% of patients develop symptoms before their 18th birthday and are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, disease courses and outcomes vary significantly between JSLE patients and individuals with adult-onset SLE. This study aimed to identify age-specific clinical and/or serological patterns in JSLE patients enrolled to the UK JSLE Cohort Study. Methods Patient records were accessed and grouped based on age at disease-onset: pre-pubertal (≤7 years), peri-pubertal (8–13 years) and adolescent (14–18 years). The presence of American College of Rheumatology (ACR) classification criteria, laboratory results, disease activity [British Isles Lupus Assessment Group (BILAG) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) scores] and damage [Systemic Lupus International Collaborating Clinics (SLICC) damage index] were evaluated at diagnosis and last follow up. Results A total of 418 JSLE patients were included in this study: 43 (10.3%) with pre-pubertal disease onset; 240 (57.4%) with peri-pubertal onset and 135 (32.3%) were diagnosed during adolescence. At diagnosis, adolescent JSLE patients presented with a higher number of ACR criteria when compared with pre-pubertal and peri-pubertal patients [pBILAG2004 scores: 9(4–20] vs. 7(3–13] vs. 7(3–14], respectively, p = 0.015] with increased activity in the following BILAG domains: mucocutaneous (p = 0.025), musculoskeletal (p = 0.029), renal (p = 0.027) and cardiorespiratory (p = 0.001). Furthermore, adolescent JSLE patients were more frequently ANA-positive (p = 0.034) and exhibited higher anti-dsDNA titres (p = 0.001). Pre-pubertal individuals less frequently presented with leukopenia (p = 0.002), thrombocytopenia (p = 0.004) or low complement (p = 0.002) when compared with other age groups. No differences were identified in disease activity (pBILAG2004 score), damage (SLICC damage index) and the number of ACR criteria fulfilled at last follow up. Conclusions Disease presentations and laboratory findings vary significantly between age groups within a national cohort of JSLE patients. Patients diagnosed during adolescence exhibit greater disease activity and “classic” autoantibody, immune cell and complement patterns when compared with younger patients. This supports the hypothesis that pathomechanisms may vary between patient age groups.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32233733</pmid><doi>10.1177/0961203320909156</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8371-7597</orcidid><orcidid>https://orcid.org/0000-0002-8911-4113</orcidid><orcidid>https://orcid.org/0000-0002-1295-6179</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0961-2033
ispartof Lupus, 2020-04, Vol.29 (5), p.474-481
issn 0961-2033
1477-0962
language eng
recordid cdi_proquest_journals_2390503512
source MEDLINE; SAGE Complete
subjects Adolescent
Adolescents
Age
Age groups
Age of Onset
Anti-DNA antibodies
Autoantibodies
Child
Child development
Clinical Laboratory Techniques
Cohort Studies
Diagnosis
Disease Progression
Female
Health risk assessment
Humans
Inflammation
Laboratories
Leukopenia
Lupus
Lupus Erythematosus, Systemic - diagnosis
Lupus Erythematosus, Systemic - pathology
Male
Patients
Rheumatology
Severity of Illness Index
Sex Factors
Systemic lupus erythematosus
Thrombocytopenia
United Kingdom
title Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A29%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20laboratory%20characteristics%20in%20juvenile-onset%20systemic%20lupus%20erythematosus%20across%20age%20groups&rft.jtitle=Lupus&rft.au=Massias,%20J%20S&rft.date=2020-04-01&rft.volume=29&rft.issue=5&rft.spage=474&rft.epage=481&rft.pages=474-481&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203320909156&rft_dat=%3Cproquest_pubme%3E2385726568%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2390503512&rft_id=info:pmid/32233733&rft_sage_id=10.1177_0961203320909156&rfr_iscdi=true